Are Analysts Bullish BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Last Week?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Logo
Investors sentiment increased to 2.43 in 2019 Q1. Its up 1.16, from 1.27 in 2018Q4. It increased, as 7 investors sold BioCryst Pharmaceuticals, Inc. shares while 21 reduced holdings. 26 funds opened positions while 42 raised stakes. 93.65 million shares or 0.54% less from 94.16 million shares in 2018Q4 were reported.
Citadel Advsr Lc invested in 2.21M shares. 69,582 are owned by Amer Gp Incorporated. Ubs Asset Mgmt Americas stated it has 61,155 shares. Federated Inc Pa invested in 779,406 shares. Tiaa Cref Invest Mgmt Ltd Liability Corporation invested in 0% or 510,408 shares. Aperio Group Llc holds 21,103 shares or 0% of its portfolio. 50,000 are held by Cheyne Cap Mgmt (Uk) Limited Liability Partnership. Daiwa Secs Group Incorporated Inc holds 0% or 697 shares in its portfolio. Bancorporation Of America De, a North Carolina-based fund reported 241,372 shares. Amalgamated National Bank & Trust holds 15,768 shares or 0% of its portfolio. Prudential Fincl reported 10,470 shares stake. 140,000 were accumulated by Hudson Bay Mgmt Ltd Partnership. Art Advsrs Limited Liability Corporation holds 0.04% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 83,230 shares. 1,000 are held by Bank & Trust Of Montreal Can. California-based Clarivest Asset Mgmt Ltd Co has invested 0.04% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Since March 12, 2019, it had 1 insider buy, and 0 insider sales for $10,710 activity.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 2 analysts covering Biocryst Pharmaceuticals (NASDAQ:BCRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Biocryst Pharmaceuticals has $18 highest and $8 lowest target. $14’s average target is 332.77% above currents $3.235 stock price. Biocryst Pharmaceuticals had 4 analyst reports since April 2, 2019 according to SRatingsIntel. On Tuesday, April 2 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The company was maintained on Tuesday, April 2 by JMP Securities. Below is a list of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) latest ratings and price target changes.

24/05/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $16.0000 4.5000
04/04/2019 Broker: BidaskScore Rating: Hold Upgrade
02/04/2019 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $6 New Target: $8 Maintain
02/04/2019 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $16 New Target: $18 Maintain

The stock decreased 2.85% or $0.095 during the last trading session, reaching $3.235. About 602,368 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined 44.97% since September 11, 2018 and is downtrending. It has underperformed by 44.97% the S&P500.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $340.20 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

More notable recent BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news were published by: Seekingalpha.com which released: “KalVista: An Early Stage Company Doing Things The Right Way – Seeking Alpha” on September 11, 2019, also Benzinga.com with their article: “The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission – Benzinga” published on August 16, 2019, Globenewswire.com published: “BioCryst to Present at Upcoming Investor Conferences – GlobeNewswire” on April 01, 2019. More interesting news about BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were released by: Globenewswire.com and their article: “BioCryst to Report Second Quarter 2019 Financial Results on August 6 – GlobeNewswire” published on July 23, 2019 as well as Seekingalpha.com‘s news article titled: “BioCryst +2.4% as director buys 3,000 shares – Seeking Alpha” with publication date: May 24, 2019.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.